1. Bonnet AM, Loria Y, Saint Hilaire MH, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson’s disease result from nondopaminergic lesions? Neurology 37: 1539–1542
2. Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH (1995) Nigral and extranigral pathology in Parkinson’s disease. J Neural Transm [Suppl] 46: 15–32
3. Chase TN, Engber TM, Mouradian MM (1996) Contribution of dopaminergic and glutaminergic mechanisms to the pathogenesis of motor response complications. Adv Neurol 69: 497–501
4. Fahn S (1996) Is Levodopa toxic? Neurology 47 Suppl 3: 184–195
5. Fahn S (1997) Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson’s disease? CNS Drugs 8(5): 376–393